Swiss pharmaceutical giant Novartis has announced plans to close MorphoSys sites in Germany, a move that will affect approximately 330 employees. The decision comes as part of Novartis’s ongoing restructuring efforts to streamline operations and focus on strategic growth areas.
The Closure
The affected sites, based in Planegg and Martinsried near Munich, were acquired by Novartis in 2020 as part of its purchase of a MorphoSys subsidiary specializing in drug development and biopharmaceuticals. The closure is expected to be completed by the end of 2025, with Novartis citing the need to align resources more effectively with its long-term goals.
“We deeply regret the impact this will have on our colleagues and are committed to supporting them through this transition,” Novartis said in a statement.
Support for Employees
Novartis has pledged to provide comprehensive support to the 330 employees impacted by the decision. This includes severance packages, career counseling, and opportunities to apply for roles within other Novartis operations.
The company emphasized its commitment to maintaining strong ties to Germany, which remains a key market and location for its research and development initiatives.
Strategic Restructuring
The closure is part of Novartis’s broader strategy to focus on high-growth therapeutic areas, including oncology, immunology, and neuroscience. The company has been divesting non-core assets and optimizing its global footprint to enhance efficiency and drive innovation.
Despite the job cuts, Novartis reaffirmed its dedication to developing breakthrough therapies and investing in cutting-edge research. “Our goal is to allocate resources where they will have the greatest impact on patients and advance our scientific priorities,” the company stated.
Industry Reaction
The decision has sparked mixed reactions within the pharmaceutical industry. While some experts see it as a necessary step for Novartis to remain competitive, others have raised concerns about the implications for Germany’s biotech sector.
MorphoSys, once a leading name in monoclonal antibody technology, had been a source of innovation and employment in the region. Its integration into Novartis was initially viewed as a boost for local biotech capabilities, making the closure particularly poignant for the local community.
Looking Ahead
As Novartis moves forward with its restructuring plans, the company faces the challenge of balancing its strategic objectives with the social and economic impact of such decisions. For the employees and communities affected, the priority will be finding new opportunities and adapting to the changing landscape of the pharmaceutical industry.
The announcement underscores the broader pressures facing the biotech sector as companies navigate the complexities of innovation, competition, and financial sustainability in an evolving global market.